# CITADEL-205 (NCT03235544)

> A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor

No report yet. It can be ordered.

- Drugs tested: parsaclisib
- Indication: relapsed or refractory mantle cell lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03235544
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Incyte Corporation
- Conditions: Lymphoma
- Interventions: Parsaclisib
- Enrollment: 162
- Primary outcome: Objective Response Rate (ORR)

## Indexed commentary on CITADEL-205 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=citadel-205-nct03235544